FibroGen rises on mid-stage trial completion for cancer treatment

Kyntra Bio

25/01/2024 17:08

** Therapy developer FibroGen's  FGEN.O  shares rise ~14.6%
to $1.10 
    ** Co says it completed a mid-stage trial evaluating its
therapy pamrevlumab in combination with chemotherapy for
pancreatic cancer treatment 
    ** Fibrogen says data from trial is expected in Q2 2024
    ** Up to last close, stock down 95.3% in last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))